LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: European Centre for Disease Prevention and Control
Languages: English
Types: Article
Subjects:
: The contribution of travel to high incidence countries and the impact of the discontinuation of universal Bacillus Calmette–Guérin (BCG) vaccination to there cent rise in tuberculosis (TB) in the United Kingdom remain unclear. An outbreak in a college presented an opportunity to assess these. A cohort of students answered a questionnaire assessing risk factors for TB.Participants were screened with an interferon gamma release assay (IGRA). Unadjusted and adjusted odds ratios (OR) were calculated using logistic regression.Among 2,284 students, 400 (17.5%) were diagnosed with TB infection. A higher risk was noted for travel to a high incidence area in the past two years (OR: 1.39;95% confidence interval (CI): 1.04–1.89) and among those with the greatest exposure to the index case(OR: 3.94; 95% CI: 2.60–5.97). There was no association between BCG and risk of infection (OR: 1.05; 95%CI: 0.80–1.39). The lack of a protective effect by BCG on TB infection supports the discontinuation of universal vaccination. The association with foreign travel suggests the need to assess the cost-effectiveness of serial IGRA testing and treatment of positive persons among returning travellers.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006. Available from: http://guidance.nice.org.uk/CG33/Guidance/pdf/English
    • 2. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(RR-15):1-47.
    • 3. Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. Tuber Lung Dis. 1992;73(2):73-6.
    • 4. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR. Tuberculosis among foreign-born persons in the United States. JAMA. 2008;300(4):405-12.
    • 5. Haddad MB, Wilson TW, Ijaz K, Marks SM, Moore M. Tuberculosis and homelessness in the United States, 1994- 2003. JAMA. 2005;293(22):2762-6.
    • 6. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax. 2007;62(8):667-71.
    • 7. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173-80.
    • 8. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29-35.
    • 9. Sutherland I, Springett VH. Effectiveness of BCG vaccination in England and Wales in 1983. Tubercle. 1987;68(2):81-92.
    • 10. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J. 1977;2(6082):293-5.
    • 11. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis. 1994;75(3):179-80.
    • 12. Donaldson L, Beasley C, Smith J. PL CMO (2005)3: Changes to the BCG vaccination programme: London: Department of Health; 6 Jul 2005.Available from: http://www.dh.gov. uk/en/Publicationsandstatistics/Lettersandcirculars/ Professionalletters/Chiefmedicalofficerletters/DH_4114993
    • 13. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 1996;45(RR-4):1-18.
    • 14. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366(9495):1443-51.
    • 15. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-84.
    • 16. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177(10):1164-70.
    • 17. Kik SV, Franken WPJ, Mensen M, Cobelens FGJ, Kamphorst M, Arend SM, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J. 2010;35(6):1346-53.
    • 18. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE. 2008;3(1):e1379.
    • 19. Abubakar I, Matthews T, Harmer D, Okereke E, Crowford K, Hall T, et al. Assessing an outbreak of tuberculosis in an English college population. Eur Respir J. Forthcoming.
    • 20. Crofts JP, Gelb D, Andrews N, Delpech V, Watson JM, Abubakar I. Investigating tuberculosis trends in England. Public Health. 2008;122(12):1302-10.
    • 21. Paranjothy S, Eisenhut M, Lilley M, Bracebridge S, Abubakar I, Mulla R, et al. Extensive transmission of Mycobacterium tuberculosis from 9 year old child with pulmonary tuberculosis and negative sputum smear. BMJ. 2008;337:a1184.
    • 22. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361(9364):1168-73.
    • 23. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353(9151):444-9.
    • 24. Cobelens FG, van Deutekom H, Draayer-Jansen IW, ScheppBeelen AC, van Gerven PJ, van Kessel RP, et al. Association of tuberculin sensitivity in Dutch adults with history of travel to areas of with a high incidence of tuberculosis. Clin Infect Dis. 2001;33(3):300-4.
    • 25. Cobelens FG, van Deutekom H, Draayer-Jansen IW, ScheppBeelen AC, van Gerven PJ, van Kessel RP, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet. 2000;356(9228):461-5.
    • 26. Ormerod LP, Green RM, Gray S. Are there still effects on Indian Subcontinent ethnic tuberculosis of return visits?: a longitudinal study 1978-97. J Infect. 2001;43(2):132-4.
    • 27. Singh H, Joshi M, Ormerod LP. A case control study in the Indian subcontinent ethnic population on the effect of return visits and the subsequent development of tuberculosis. J Infect. 2006;52(6):440-2.
    • 28. Abubakar I, Moore J, Drobniewski F, Kruijshaar M, Brown T, Yates M, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax. 2009;64(6):512-5.
    • 29. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009;373(9678):1861-73.
    • 30. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2006;(2). CD005435
    • 31. Rodrigues LC, Diwan VK, Wheeler JG. Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis. Int J Epidemiol. 1993;22(6):1154-8.
    • 32. Eisenhut M, Paranjothy S, Abubakar I, Bracebridge S, Lilley M, Mulla R, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine. 2009;27(44):6116-20.
    • 33. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339-45.
    • 34. Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Public Health. 2008;8:201
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article